{"id":1459,"date":"2026-05-15T15:10:35","date_gmt":"2026-05-15T15:10:35","guid":{"rendered":"https:\/\/wp-productionenv-bjg9h2g2bgg5b8aa.southeastasia-01.azurewebsites.net\/news\/voyager-technologies-awarded-new-mission-management-contract-with-exobiosphere\/"},"modified":"2026-05-15T15:10:35","modified_gmt":"2026-05-15T15:10:35","slug":"voyager-technologies-awarded-new-mission-management-contract-with-exobiosphere","status":"publish","type":"post","link":"https:\/\/starpath.global\/news\/voyager-technologies-awarded-new-mission-management-contract-with-exobiosphere\/","title":{"rendered":"Voyager Technologies Awarded New Mission Management Contract With Exobiosphere"},"content":{"rendered":"

<\/p>\n

\"Voyager<\/p>\n

Voyager Technologies<\/strong> and Exobiosphere<\/strong> announced a mission management contract on the International Space Station (ISS) that marks a concrete step toward making automated biological research in microgravity commercially accessible to researchers, agencies, pharmaceutical and biotech partners. <\/p>\n

\u201cOur mission management services exist to build a clear path for innovative ideas to become a reality in space,\u201d said Matt Maga\u00f1a<\/strong>, president of Space, Defense and National Security, Voyager.<\/strong> \u201cFacilitating this access to the ISS is critical to improving life here on Earth, and irrespective of platform, we have a proven path to do that.\u201d<\/p>\n

Under the contract, Voyager Technologies Europe will serve as mission integrator for the Orbital High-Throughout Screener (OHTS), Exobiosphere\u2019s miniaturized platform aboard the ISS. Voyager will also provide project management support, including safety and verification to the NASA Safety Review standards, integration aboard the ISS and coordination of on-orbit operations for the installed OTHS payload. <\/p>\n

\u201cOur agency, research, and biotech partners have been telling us the same thing: they need high-throughput automated systems, increased access, and a higher cadence,” said Kyle Acierno<\/strong>, CEO of Exobiosphere<\/strong>. \u201cHardware on station means we can serve partners continuously and start building the operational track record that opens the door to pharma and biotech at scale.\u201d<\/p>\n

\n

Also Read: Orbiting Microgravity Factories: Potential to Disrupt Terrestrial Industries<\/h4>\n<\/div>\n

Built for repeat use, the OHTS architecture is modular: samples and consumable elements can be exchanged between campaigns, giving pharmaceutical and biotech clients a continuous pipeline of experiments without requiring a new hardware deployment each time. Follow-on contracts are expected. <\/p>\n

\u201cOHTS is the first payload of its kind, capable of running over 2,000 simultaneous drug screening samples in a single mission, with integrated brightfield and fluorescence microscopy, luminescence reading, and fully autonomous media and reagent exchange,\u201d said Olivia Borgue<\/strong>, co-founder and director of Engineering, Exobiosphere<\/strong>. \u201cHaving Voyager\u2019s expertise in ISS integration and mission management by our side means we can focus entirely on advancing the science and delivering real value to our clients.\u201d<\/p>\n

The contract reinforces Voyager\u2019s track record of facilitating access to low-Earth orbit and advances Exobiosphere\u2019s mission to improve life on Earth through microgravity research. <\/p>\n

\u201cVoyager Technologies Europe is committed to supporting Europe\u2019s growing ambitions in Low Earth Orbit by working with International Space Station capabilities today and preparing for the next phase of commercial space stations with Starlab,\u201d said Mattia Pianorsi<\/strong>, managing director, Voyager Technologies Europe.<\/strong> \u201cOur presence in Europe allows us to work closely with regional partners and institutions, turning advanced concepts into operational missions.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Voyager Technologies and Exobiosphere announced a mission management contract on the International Space Station (ISS) that marks a concrete step toward making automated biological research in microgravity commercially accessible to researchers, agencies, pharmaceutical and biotech partners.  \u201cOur mission management services exist to build a clear path for innovative ideas to become a reality in space,\u201d […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[41,26,76,20],"class_list":["post-1459","post","type-post","status-publish","format-standard","hentry","category-news","tag-defense","tag-ground","tag-payload-adapters","tag-satellite"],"acf":[],"_links":{"self":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts\/1459"}],"collection":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/comments?post=1459"}],"version-history":[{"count":0,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts\/1459\/revisions"}],"wp:attachment":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/media?parent=1459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/categories?post=1459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/tags?post=1459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}